The company offers a range of DNA and RNA based tests for various medical conditions, including infectious diseases, oncology, endocrinology, transplantation typing, haematology, pharmacogenetics, and pre-natal and pre-implantation genetic diagnostics. GenePath Dx uses proven platform technologies such as quantitative/real-time polymerase chain reaction, multiplex ligation-dependent probe amplification, and Sanger and Next Generation Sequencing. Their molecular tests are faster and more sensitive than traditional methods, making them essential for diagnosing an increasing number of conditions. Founded in 2012 by Nikhil Phadke, the company is focused on continuous research and development to stay at the forefront of the industry.